Mechanisms of Repression by Polycomb Proteins

Imprimer la page

-A +A
Group leader : R. Margueron
Mechanisms of Repression by Polycomb Proteins

Keywords

Polycomb, Chromatin, Biochemistry, Methylation, Cancer

Plain english

Polycomb Group Proteins maintain gene silencing throughout development and adulthood by interfering with chromatin structure. Depending on the cell type, distinct sets of genes get targeted by these proteins. How is this cell specificity established and maintained, what happen when the machinery gets awry are the main questions that we are investigating.

 

 

Polycomb Group (PcG) proteins maintain the pattern of gene expression of different cells set early during development by regulating chromatin structure. Consequently interfering with PcG proteins expression affects various biological processes such as differentiation, proliferation or maintenance of pluripotency. In addition, PcG genes are found deregulated in various pathologies including cancer.

Chromatin structure is defined by several parameters such as combination of histone post-translational marks, nucleosome occupancy, DNA methylation or incorporation of histone variants. Chromatin structure contributes to the epigenetic regulation of gene expression, DNA replication or DNA repair. The polycomb complex PRC2 maintains gene silencing throughout development and is responsible for the di- and tri- methylation of histone H3 lysine 27 (figure 1). This post-translational mark is associated to parts of the genome that are either weakly transcribed or silent.

Considering its importance in modulating various biological processes, the PRC2 complex is tightly regulated. Hence, it has been shown that in addition to its four core components, the PRC2 complex comprises additional cofactors (Jarid2, Pcl, AEBP2) that are required for its functioning. PRC2 components are also subjected to post-translational modifications. Finally, long non-coding RNAs interact with PRC2. How all those regulatory cues (figure 2) come together to orchestrate the activity of PRC2 remains unclear.

The PRC2 component, Ezh2, was found to be upregulated in advanced stages of prostate and breast cancer (Figure 3). Furthermore, its level of expression is correlated to poor outcome. In contrast, somatic mutations interfering with the enzymatic activity of Ezh2 were reported in subtypes of lymphoma. Hence, both upregulation and inactivation of Ezh2 could have deleterious consequences. How modulating Ezh2 interferes with the tumorigenic process? Is PRC2 deregulation a leading event in this process? ...

fig 1:Schematic representation of chromatin structurefig 1:Schematic representation of chromatin structure

Fig2. Schematic representation of pathways regulating PRC2.Fig2. Schematic representation of pathways regulating PRC2.

Fig 3:Ezh2 and PCNA expression in a mouse model of prostate cancer based on the overexpression c-myc (HM)Fig 3:Ezh2 and PCNA expression in a mouse model of prostate cancer based on the overexpression c-myc (HM)

Key publications